key: cord-0715054-cafm0g29
authors: Roberts, G. H. L.; Partha, R.; Rhead, B.; Knight, S. C.; Park, D. S.; Coignet, M. V.; Zhang, M.; Berkowitz, N.; Turrisini, D. A.; Gaddis, M.; McCurdy, S. R.; Pavlovic, M.; Ruiz, L.; Banda, Y.; Bi, K.; Burton, R.; Champine, M.; Curtis, R.; Delgado, K.; Drokhlyansky, A.; Elrick, A.; Foo, C.; Gu, J.; Harris, H.; King, S.; Maldonado, C.; McCartney-Melstad, E.; Miller, P.; Noto, K.; Pei, J.; Petersen, J.; Sass, C.; Sedghifar, A.; Smelter, A.; South, S.; Starr, B.; Vaughn, C.; Wang, Y.; Haug Baltzell, A. K.; Guturu, H.; Girshick, A. R.; Rand, K. A.; Hong, E. L.; Ball, C. A.
title: Novel COVID-19 phenotype definitions reveal phenotypically distinct patterns of genetic association and protective effects
date: 2021-01-26
journal: nan
DOI: 10.1101/2021.01.24.21250324
sha: 93dd5c96cbe1ab61e117d3a424f8bf6f3c3b195c
doc_id: 715054
cord_uid: cafm0g29

Multiple large COVID-19 genome-wide association studies (GWAS) have identified reproducible genetic associations indicating that some infection susceptibility and severity risk is heritable. Most of these studies ascertained COVID-19 cases in medical clinics and hospitals, which can lead to an overrepresentation of cases with severe outcomes, such as hospitalization, intensive care unit admission, or ventilation. Here, we demonstrate the utility and validity of deep phenotyping with self-reported outcomes in a population with a large proportion of mild and subclinical cases. Using these data, we defined eight different phenotypes related to COVID-19 outcomes: four that align with previously studied COVID-19 definitions and four novel definitions that focus on susceptibility given exposure, mild clinical manifestations, and an aggregate score of symptom severity. We assessed replication of 13 previously identified COVID-19 genetic associations with all eight phenotypes and found distinct patterns of association, most notably related to the chr3/SLC6A20/LZTFL1 and chr9/ABO regions. We then performed a discovery GWAS, which suggested some novel phenotypes may better capture protective associations and also identified a novel association in chr11/GALNT18 that reproduced in two fully independent populations.

Multiple large COVID-19 genome-wide association studies (GWAS) have identified 16 reproducible genetic associations indicating that some infection susceptibility and severity risk is 17 heritable. 1-5 Most of these studies ascertained COVID-19 cases in medical clinics and hospitals, 18 which can lead to an overrepresentation of cases with severe outcomes, such as hospitalization, 19

intensive care unit admission, or ventilation. Here, we demonstrate the utility and validity of 20 deep phenotyping with self-reported outcomes in a population with a large proportion of mild 21 and subclinical cases. Using these data, we defined eight different phenotypes related to 22 COVID-19 outcomes: four that align with previously studied COVID-19 definitions and four 23 novel definitions that focus on susceptibility given exposure, mild clinical manifestations, and an 24 aggregate score of symptom severity. We assessed replication of 13 previously identified 25 COVID-19 genetic associations with all eight phenotypes and found distinct patterns of 26 association, most notably related to the chr3/SLC6A20/LZTFL1 and chr9/ABO regions. We then 27 performed a discovery GWAS, which suggested some novel phenotypes may better capture 28 protective associations and also identified a novel association in chr11/GALNT18 that 29 reproduced in two fully independent populations. 30

To perform genetic studies of COVID-19, we conducted a comprehensive, 50+ question survey 32 of AncestryDNA customers that assessed exposure, risk factors, symptomatology, and 33 demographic information (Supplementary Figure 1; Supplementary Table 1 ). We collected 34 over 700,000 COVID-19 survey responses between April and August 2020 and used them to 35 develop an expanded repertoire of phenotypes to investigate. In total, we defined eight 36 COVID-19 phenotypes, summarized in Table 1 . Four phenotypes were intended to mirror 37 susceptibility or severity phenotype definitions from other large COVID-19 GWAS 2,3 and four 38 are novel. We hypothesized that novel phenotype definitions focusing on mild outcomes or 39 absence of infection despite a strong exposure may be better suited to detecting protective 40 genetic associations than traditional phenotypes. 41 42 Susceptibility to infection is difficult to measure because contracting the virus depends on 43 exposure. We therefore designed two novel susceptibility phenotypes that focus on respondents 44 with a known, strong exposure to the virus-those who had "household exposure." The 45 positivity rate among respondents that reported a housemate with confirmed COVID-19 was 46 approximately 65%, the highest positivity rate for any exposure we assessed. The 47 Exposed_Positive/Exposed_Negative phenotype compared those with a household exposure that 48 tested positive to those with a household exposure that tested negative, and 49

Associations near ABO, the gene that determines blood type, have also been observed in multiple 101 COVID-19 GWAS-somewhat inconsistently with severity phenotypes and more consistently 102 with susceptibility phenotypes (Supplementary Table 5 ). The lead ABO SNP, rs505922, 103 replicated in all four susceptibility phenotypes plus one severity phenotype. The only severity 104 phenotype associated with the ABO SNP was Hospitalized/Unscreened, which utilized a large 105 number of unscreened controls. We speculate that unscreened controls induce susceptibility 106 associations because hospitalized cases must be susceptible to infection, but the unscreened 107 control group may or may not be susceptible, and thus this phenotype simultaneously captures 108 aspects of both susceptibility and severity. 109 110 Our second goal was to discover novel phenotype-locus associations; we therefore conducted a 111 discovery GWAS for all eight phenotypes. Due to the novelty of the phenotypes and the 112 difficulty in obtaining a truly independent COVID-19 replication cohort, we opted to conduct the 113 discovery GWAS in the same EUR cohort used in the above trans-ancestry meta-analysis, and 114 dedicate a smaller, fully independent EUR cohort, the LAT cohort, and the AA cohort to 115 determining whether any newly identified phenotype-locus associations reproduce. 116

No phenotype-locus association pairs surpassed a conservative Bonferroni-corrected significance 118 threshold of discovery P<6.25x10 -9 , but we examined associations that reached a suggestive 119 significance threshold of P<1x10 -5 to look for trends. In total, we identified 297 suggestive 120 phenotype-locus association pairs (Supplementary Table 6 ). Strikingly, minor alleles 121 suggestively associated with three novel phenotypes (Exposed_Positive/Exposed_Negative, 122 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250324 doi: medRxiv preprint with a protective direction of effect, whereas for all previously studied phenotypes, the minor 124 allele was nearly always associated in the risk direction (Figure 3 ). This finding supports our 125 hypothesis that the novel phenotype definitions that focus on mild outcomes or absence of 126 infection despite a strong exposure may be better suited to detecting protective genetic 127 associations than traditional phenotypes. There were also 15 phenotype-locus association pairs that reproduced in one independent 139 population, and one that replicated in two independent populations (Supplementary Table 8) . 140

The phenotype-locus association that replicated in two fully independent populations was 141 chr11 in the gene GALNT18. Interestingly, another SNP within GALNT18 was previously 143 reported as associated with an increased response to Tocilizumab 6 , an IL-6 blocking monoclonal 144 antibody that has been tested in multiple clinical trials for treatment of COVID-19, albeit with 145 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250324 doi: medRxiv preprint mixed preliminary success. 7-9 Nonetheless, this novel association with GALNT18 complements 146 findings by other genetic studies that point to modulation of the IL-6 pathway as a potential 147 strategy to ameliorate severe COVID-19 in some people. 10 148 149

In summary, we explored genetic association with eight different COVID-19 phenotype 150 definitions, four of which have not yet been explored. We find that 10 of 13 previously identified 151 COVID-19 genetic signals associate with at least one of the eight phenotype definitions. This 152 strong replication of loci identified by clinically ascertained studies confirms that phenotyping 153 based on well-designed self-report studies is valid. Some of these replicated genetic signals 154 clearly associate more with severity phenotypes and others associate more with susceptibility 155 phenotypes, suggesting that heterogeneity in ascertainment and different case/control definitions 156 likely underlies inconsistent associations, for instance ABO. Our findings also show that all three 157 previously identified signals in the chr3 LZTFL1/SLC6A20 region associate with a different set 158 of phenotypes, suggesting that variation in this region modulates multiple aspects of COVID-19 159 susceptibility and severity and thus is extremely important. In our discovery analysis, we 160 identified a novel association with rs55673936, a GALNT18 intron variant that reproduced in 161 multiple independent populations. Whereas other groups with primary ascertainment at medical 162 clinics are better equipped to study severe outcomes, our self-reported dataset allows a 163 complementary analysis of more granular phenotypes in a population enriched for mild 164 outcomes. We find promising evidence that exploring new phenotypes in this unique population 165 will yield novel genetic associations, particularly those that confer protection against the novel 166 coronavirus. 167 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250324 doi: medRxiv preprint

All data for this research project were from subjects who provided prior informed consent to 170 participate in AncestryDNA's Human Diversity Project, as reviewed and approved by our 171 external institutional review board, Advarra (formerly Quorum). All data were de-identified prior 172 to use. To participate in the COVID-19 survey, participants must meet the following criteria: they must 183 be 18 years of age or older, a resident of the United States, be an existing AncestryDNA 184 customer who has consented to participate in research and be able to complete a short survey. 185

The survey is designed to assess self-reported COVID-19 positivity and severity, as well as 186 susceptibility and known risk factors including community exposure and known contacts with 187 individuals diagnosed with COVID-19. 188 189 190 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250324 doi: medRxiv preprint

In total, we assessed eight phenotypes, which are summarized in Table 1 . Key definitions 192 include testing positive or negative, hospitalization, asymptomatic cases, and housemate 193 exposure. COVID-19 positivity or negativity was assessed by the question "Have you been swab 194 tested for COVID-19, commonly referred to as coronavirus?". Hospitalization due to illness was used as one binary measure of severity, and was assessed with the question, "Were 196 you hospitalized due to these symptoms?". Asymptomatic cases were defined as those that were 197 positive for COVID-19 and either answered "No" do the question "Did you experience 198 symptoms as a result of your condition?" or answered either "None", "Very mild", or "Mild" to 199 all 15 questions related to symptom severity. High exposure to COVID-19 was assessed through ventilation, septic shock, respiratory failure, and organ failure due to COVID-19. Binary 208 responses were encoded as 0 for "No" and 1 for "Yes". Three symptom questions related to 209 shortness of breath, fever, and nausea/vomiting symptoms were encoded as a unit-scaled variable 210 based on the following mapping: 0="None", 0.2="Very mild", 0.4="Mild", 0.6="Moderate", 211 0.8="Severe", and 1.0="Very Severe". The three symptoms were chosen based on prior 212 literature indicating their positive association with COVID-19 hospitalization. 11 The following 213 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250324 doi: medRxiv preprint assumptions were made to so that a score could be calculated for most participants who reported 214 a positive COVID-19 test: 215

• Participants who responded "No" to the question "Did you experience symptoms as a 216 result of your condition?" were not presented with additional questions regarding 217 symptomatology or hospitalization and thus were encoded as 0 for all individual 218 symptoms (shortness-of-breath, fever, nausea/vomiting), hospitalization, ICU admittance, 219 and severe complications due to COVID-19 illness. 220

• Participants who responded "No" to the question "Were you hospitalized due to these 221 symptoms?" were not presented any further questions regarding hospitalization and thus 222 were encoded as 0 for ICU admittance and supplemental oxygen. 223

• Participants who declined to answer a question about complications due to COVID-19 224 illness such as septic shock, respiratory failure, and organ failure were encoded as 0 for 225 those complications (<2% of all participants for whom continuous severity was scored). 226

Genotyping 228

Genotyping and quality control procedures have been previously described elsewhere. 12 Briefly, 229 customer genotype data for this study were generated using an Illumina genotyping array and 230 processed either with Illumina or with Quest/Athena Diagnostics. To ensure quality of each 231 dataset, a sample passes a number of quality control (QC) checks, which includes identifying 232 duplicate samples, removing individuals with a per-sample call rate <98%, and identifying 233 discrepancies between reported sex and genetically inferred sex. Samples that pass all quality-234 control tests proceed to the analysis pipeline; samples that fail one or more tests must be 235 recollected or manually cleared for analysis by lab technicians. Array markers with per-variant 236 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. were not assigned to any ancestry group (Supplementary Table 1) . 251 252

AncestryDNA's identity-by-descent inference algorithm 13 was used to estimate the relationship 254 between pairs of individuals. Pairs with estimated separation of fewer than four meioses were 255 considered close relatives. For all close relative pairs, one individual was randomly selected for 256 exclusion from our study. In total, we excluded ~8% (60,379) individuals from analysis due to 257 relatedness. 258 259 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250324 doi: medRxiv preprint For each population described above, genetic PCs were calculated to include in the association 261 studies to control residual population structure and were computed using FlashPCA 2.0. 14 Input 262 genotypes were linkage disequilibrium (LD)-pruned using PLINK 1.9 command --indep-pairwise 100 5 0. genetic model was implemented with PLINK2.0. Imputed genotype dosage value was the 280 primary predictor. The following were included as fixed-effect covariates: PCs 1-25 (described 281 above), array platform, orthogonal age, and orthogonal age 2 . Orthogonal polynomials were used 282 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. Unless otherwise noted, all EUR discovery variant effect estimates are adjusted for the 28 302 covariates described above. To establish significance, we implemented a stringent, Bonferroni-303 corrected significance threshold by dividing the typical genome-wide significance threshold in 304

Europeans of P<5x10 -8 by the eight phenotypes, which results in P<6.25x10 -9 . Suggestive 305 significance followed the definition used by the HGI consortium of P<1x10 -5 . 306 307 Independent Replication GWAS 308 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250324 doi: medRxiv preprint

We began reserving respondents for the replication EUR cohort at the conclusion of our previous 310 study 12 on May 28, 2020, and thus the replication EUR cohort is not representative of the full 311 period of survey collection. The AA and LAT cohorts were steadily collected throughout the 312 entire collection period that spanned April 22, 2020 to August 3, 2020. We conducted separate 313 GWAS for each of these three replication cohorts and for each of the eight phenotypes. The same 314 association procedure that was used for the discovery study was applied for replication cohorts, 315 except sample sizes for these cohorts were smaller (Supplementary Table 2) , and thus a single 316 GWAS was conducted for males and females together with genetic sex included as a covariate. 317 318

For each phenotype, we additionally performed a trans-ancestry meta-analysis of the discovery 320 EUR cohort, AA, and LAT summary statistics, again using fixed-effect inverse-variance 321 weighting implemented in METAL. The replication EUR cohort was not included in the trans-322 ancestry meta-analysis. These summary statistics were used to assess replication of the 13 loci 323 defined in the next section. 324 325

We manually curated a list of 13 independent SNPs that represent lead loci identified by either 327 HGI or Horowitz et al. Eight of the 13 SNPs were lead SNPs in HGI's most recent data release 328 (October 2020; without 23andMe data included). These eight SNPs were the most-associated 329 marker at any locus achieving P<5x10 -8 in the Hospitalization vs. Population ("ANA_B2") or 330 COVID-19(+) vs. Population ("ANA_C2"). The remaining five SNPs were selected from Figure  331 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250324 doi: medRxiv preprint respondents overlap those included in the large meta analyses conducted by HGI and Horowitz et 333 al. and thus replication in our study is not completely independent (Supplementary Figure 3) . 334

All 13 SNPs in the final list are independent of one another (r 2 <0.05) and represent 11 335 positionally distinct loci (>500Kb apart). One of the 11 loci encompasses three independent 336

SNPs that span a 52Kb region near SLC6A20/LZTFL1 on chr3. For these 13 index SNPs, we 337 extracted corresponding summary statistics from the trans-ancestry meta-analysis for each 338 phenotype. We computed the -log10(P-value) from the trans-ancestry meta-analysis, setting any 339 trans-ancestry P>0.05 or with inconsistent directions of effect compared to the previous study 340 equal to zero. From the resulting matrix of -log10(P-values), we generated a heatmap with R 341 package pheatmap, and used hierarchical clustering to order the phenotype rows and the SNP 342 columns in an unsupervised fashion. 343 344

Within the discovery EUR GWAS, we identified all loci that were suggestively associated 346 (discovery EUR P<1x10 -5 ) with any phenotype. For each of these suggestive associations, we 347 designated the SNP with the lowest EUR P-value within a 500kb window the index SNP. From 348 the resulting set of suggestive phenotype-locus association pairs, we determined whether the 349 association replicated in one or more independent GWAS (replication EUR, LAT, or AA). We is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250324 doi: medRxiv preprint phenotype-locus association pairs, there was another SNP that surpassed discovery EUR 355 P<1x10 -5 in the same region (<500Kb from the index SNP) and the alternative SNP was included 356 in both non-EUR GWAS, so we used this alternative SNP to assess replication in the non-EUR 357 cohorts. We also measured the Pearson correlation coefficient of ̂ between the discovery 358 EUR study and each of the three independent replication cohorts. 359

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. relative to the previous study were forced to have -log10(P-value)=0. SNP and phenotype labels 381 were ordered by hierarchical clustering, with corresponding dendrograms shown on the top and 382 left of the figure. Orange rectangles annotate phenotypes or loci that appear to associate more 383 strongly with severity whereas blue rectangles annotate phenotypes or loci that appear to 384 associate more strongly with susceptibility. Extended summary statistics for all associations in 385 all studies are available in Supplementary Table 4 . 386 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250324 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250324 doi: medRxiv preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250324 doi: medRxiv preprint

Genomewide Association Study of Severe Covid-19 with 441 Respiratory Failure

Common genetic variants identify therapeutic targets for COVID-19 443 and individuals at high risk of severe disease. medRxiv

The COVID-19 Human Genetics Initiative, COVID-19 HGI Results for Data Freeze

Genetic mechanisms of critical illness in Covid-19

Trans-ethnic analysis reveals genetic and non-genetic associations 449 with COVID-19 susceptibility and severity. medRxiv

Genetic and clinical biomarkers of tocilizumab response in 452 patients with rheumatoid arthritis

Interleukin-6 Receptor Antagonists in Critically Ill 454 Patients with Covid-19 -Preliminary report. medRxiv

Pharmacologic 456 Treatments for Coronavirus Disease 2019 (COVID-19): A Review

Pharmacogenomics of 459 COVID-19 therapies

Genetically proxied interleukin-6 receptor 461 inhibition: opposing associations with COVID-19 and pneumonia

COVID-19 Susceptibility and Severity Risks in a Survey of Over 463 500,000 People. medRxiv

AncestryDNA COVID-19 Host Genetic Study Identifies Three 465 Novel Loci. medRxiv

AncestryDNA Matching White Paper: Discovering genetic matches 467 across a massive, expanding genetic database

FlashPCA2: principal component analysis of 469 Biobank-scale genotype datasets

METAL: fast and efficient meta-analysis of 472 genomewide association scans

We thank our AncestryDNA customers who made this study possible by voluntarily contributing 431